SCHEMBL7015564

SCHEMBL7015564

COc1ccccc1CN.O=C(O)c1ccc2cccnc2n1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
KDM4E B2RXH2 4/20 0.60
LMNA P02545 1/20 0.60
TDP1 Q9NUW8 1/20 0.42
ASPH Q12797 1/20 0.42
KDM8 Q8N371 1/20 0.42
BCHE P06276 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
POLB P06746 1/20 0.39
ECE1 P42892 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
CNR2 P34972 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
MGAM O43451 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7536798 0.85 MEN1 (0.53) MEN1KMT2AKDM4ELMNAPOLB
Methoxymethane SCHEMBL27938732 0.81 KDM4E (0.87) MEN1KMT2AKDM4ELMNATDP1
SCHEMBL7016470 0.79 MEN1 (0.71) MEN1KMT2AKDM4ELMNATDP1
SCHEMBL125654 0.78 KDM4E (1.00) MEN1KMT2AKDM4ELMNATDP1
SCHEMBL30505600 0.78 KDM4E (1.00) MEN1KMT2AKDM4ELMNATDP1
SCHEMBL30381290 0.78 KDM4E (1.00) MEN1KMT2AKDM4ELMNATDP1
Trifluoroacetic Acid SCHEMBL7010257 0.77 GRIN2B (0.49) MEN1KMT2AKDM4ELMNATDP1
SCHEMBL7016188 0.77 GRIN2B (0.57) MEN1KMT2AKDM4ELMNATDP1
SCHEMBL27359670 0.76 LMNA (0.41) MEN1KMT2AKDM4ELMNATDP1
Fluoride SCHEMBL28821496 0.76 KDM4E (0.96) MEN1KMT2AKDM4ELMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6605614-B2 Anti-hepatitis or anti-herpes BIOCHEM PHARMA INC. (CA) 2003-08-12 US disclosed
EP-1155017-B1 [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY SHIRE BIOCHEM INC (CA) 2003-01-15 EP disclosed
US-20020099072-A1 [1,8] naphthyridine derivatives having antiviral activity BIOCHEM PHARMA INC. 2002-07-25 US disclosed
US-6340690-B1 INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS BIO-CHEM PHARMA INC. (CA) 2002-01-22 US disclosed
EP-1155017-A1 [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY Shire Biochem Inc. (CA) 2001-11-21 EP disclosed
WO-2000050424-A1 [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY BIOCHEM PHARMA INC. (CA) 2000-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099072-A1 [1,8] naphthyridine derivatives having antiviral activity HAVCR2, MAVS, NTPCR MEN1 4721/4885KMT2A 4352/4885KDM4E 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.